trial

A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

NCTId NCT03465787
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 210 (actual)
Sponsored by Bukwang Pharmaceutical
Primary completion 2022-10-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
210 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2018-04-09
Primary completion
2022-10-26
Eligibility
ALL · 19 Years · 75 Years

Interventions & indications

Drugs
LurasidoneQuetiapine

Sponsors

Bukwang PharmaceuticalLead Sponsor

Investigators

1
Jung Hee YeonPrincipal Investigator

Sites

1 total
Seoul, South Korea

Linked catalysts

1
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely — primary completion2022-10-26

Facts & assertions

4 sourced
Enrollment
210
Phase
PHASE3
Primary Completion Date
2022-10-26
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
Quetiapine
drug
lead_sponsor
Bukwang Pharmaceutical
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jung Hee Yeon
person